GLSH Share Price Performance
US$0.000001
0.00 (0.00%)
Price US$0.000001
Share PriceUS$0.000001
GLSH Community Narratives
There are no narratives available yet.
Gelesis Holdings, Inc. Key Details
Last Reported Earnings
Jun 30, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.70
- Gross Margin
- -61.40%
- Net Profit Margin
- -425.58%
- Debt/Equity Ratio
- -325.5%
Gelesis Holdings, Inc. Competitors
Snowflake Analysis
About GLSH
- Founded
- 2006
- Employees
- 93
- CEO
- WebsiteView website
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Market Insight
Market sentiment on BTC treasury companies is moving, and with volatility rising, disagreements over their future prospects are as heated as ever.
Continue reading
U.S. Market Performance
- 7 Days: 0.5%
- 3 Months: 11.7%
- 1 Year: 15.7%
- Year to Date: 10.1%
The market has been flat over the last week. More promisingly, the market is up 16% over the past year. Earnings are forecast to grow by 15% annually. Market details ›